- Home
- BMEA vs CLLS Comparison
BMEA vs CLLS Comparison
Compare BMEA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- CLLS
- Stock Information
- Founded
- BMEA 2017
- CLLS 1999
- Country
- BMEA United States
- CLLS France
- Employees
- BMEA N/A
- CLLS N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- BMEA Health Care
- CLLS Health Care
- Exchange
- BMEA Nasdaq
- CLLS Nasdaq
- Market Cap
- BMEA 145.0M
- CLLS 148.1M
- IPO Year
- BMEA 2021
- CLLS 2007
- Fundamental
- Price
- BMEA $3.46
- CLLS $1.53
- Analyst Decision
- BMEA Buy
- CLLS Buy
- Analyst Count
- BMEA 13
- CLLS 3
- Target Price
- BMEA $27.92
- CLLS $7.00
- AVG Volume (30 Days)
- BMEA 414.8K
- CLLS 114.3K
- Earning Date
- BMEA 03-31-2025
- CLLS 11-04-2024
- Dividend Yield
- BMEA N/A
- CLLS N/A
- EPS Growth
- BMEA N/A
- CLLS N/A
- EPS
- BMEA N/A
- CLLS N/A
- Revenue
- BMEA N/A
- CLLS $36,042,000.00
- Revenue This Year
- BMEA N/A
- CLLS $387.77
- Revenue Next Year
- BMEA N/A
- CLLS $11.14
- P/E Ratio
- BMEA N/A
- CLLS N/A
- Revenue Growth
- BMEA N/A
- CLLS 46.96
- 52 Week Low
- BMEA $3.25
- CLLS $1.41
- 52 Week High
- BMEA $19.36
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- BMEA 34.96
- CLLS 45.06
- Support Level
- BMEA $3.25
- CLLS $1.51
- Resistance Level
- BMEA $3.75
- CLLS $1.62
- Average True Range (ATR)
- BMEA 0.24
- CLLS 0.09
- MACD
- BMEA 0.00
- CLLS 0.01
- Stochastic Oscillator
- BMEA 21.43
- CLLS 29.17
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.